Drug Shortage Compounding Patient Access Act of 2025
The Drug Shortage Compounding Patient Access Act of 2025 would amend the Federal Food, Drug, and Cosmetic Act to improve access to shortage- and urgent-use medications through expanded pharmacy compounding, enhanced reporting of shortages and surges in demand, and updated labeling and recordkeeping. The bill creates new conditions under which compounding pharmacists or licensed physicians may prepare and distribute non-patient-specific medications for urgent administration in hospitals or clinical settings when a drug is on a shortage list. It also strengthens the oversight of outsourcing facilities (503B) and expands public reporting on drug shortages and bulk drug substances. In short, the bill aims to speed access to critical compounded medicines during shortages while increasing transparency and accountability around shortages and adverse events. Key elements include allowing urgent-use, shortage-related compounding outside a specific patient prescription under defined safeguards; clarifying what counts as “essentially a copy” of a commercially available product; expanding the reporting requirements for drug shortages (including surges in demand) and including outsourcing facilities in those requirements; updating the public list of bulk drug substances; and adding labeling and recordkeeping requirements to ensure clarity about compounded products and to support traceability and safety.